Credence Research Logo

Home » Biotechnology » Biopharmaceuticals Contract Manufacturing Market

Biopharmaceuticals Contract Manufacturing Market By Source (Mammalian, Non-mammalian); By Service (Process Development, Downstream, Upstream, Fill & Finish Operations, Analytical & QC Studies, Packaging & Labelling, Others); By Drug Type (Biologics, Monoclonal Antibodies [mAbs], Recombinant Proteins, Vaccines, Antisense, RNAi & Molecular Therapy, Others, Biosimilars); By Type (Drug Substance, Finished Drug Product); By Scale of Operation (Clinical, Commercial); By Therapeutic Area (Oncology, Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Others); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $4699

Published: | Report ID: 68099 | Report Format : PDF
REPORT ATTRIBUTE DETAILS
Historical Period  2019-2022
Base Year  2023
Forecast Period  2024-2032
Biopharmaceutical Contract Manufacturing Market Size 2024  USD 16,029.84 Million
Biopharmaceutical Contract Manufacturing Market, CAGR  15.50%
Biopharmaceutical Contract Manufacturing Market Size 2032  USD 58,636.37 Million

Market Overview

The Global Biopharmaceutical Contract Manufacturing Market is projected to grow from USD 16,029.84 million in 2023 to USD 58,636.37 million by 2032, at a compound annual growth rate (CAGR) of 15.50%.

The global biopharmaceutical contract manufacturing market is driven by the increasing demand for biologics, particularly monoclonal antibodies and vaccines, which require complex and scalable production processes. Advancements in biomanufacturing technologies, such as continuous processing and single-use systems, are enhancing production efficiency and reducing costs. Additionally, the rising outsourcing trend among pharmaceutical companies, seeking cost-effective solutions and improved production flexibility, is further fueling market growth. The growing adoption of biologics in therapeutic areas like oncology, immunology, and infectious diseases also contributes to this demand. Moreover, the expansion of healthcare access in emerging markets and increased government investments in biopharmaceuticals are accelerating the need for contract manufacturing services. Trends such as personalized medicine and the development of gene and cell therapies are shaping the future of the industry, presenting both challenges and opportunities for contract manufacturers to innovate and adapt to evolving demands in the biopharmaceutical sector.

The global biopharmaceuticals contract manufacturing market is geographically diverse, with key players operating across various regions to meet increasing demand for outsourced manufacturing services. North America holds a significant share due to the presence of major pharmaceutical companies and advanced biomanufacturing technologies. Europe follows closely, driven by strong healthcare systems and regulatory support for biologics production. In the Asia Pacific region, countries like China and India are witnessing rapid growth, owing to cost-effective manufacturing solutions and a large pool of skilled labor. Key players in this market include Boehringer Ingelheim GmbH, Lonza, WuXi Biologics, Samsung Biologics, and Thermo Fisher Scientific, Inc. These companies are focusing on expanding their production capabilities, enhancing process development services, and offering a wide range of contract manufacturing solutions to cater to the growing global demand for biopharmaceuticals. Their strategic collaborations, technological advancements, and global presence are key drivers of market growth.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Insights

  • The global biopharmaceuticals contract manufacturing market is expected to grow from USD 16,029.84 million in 2023 to USD 58,636.37 million by 2032, at a CAGR of 15.50%.
  • Increasing demand for biologics and biosimilars is driving the market as companies seek cost-effective manufacturing solutions.
  • The trend towards outsourcing drug manufacturing and process development is gaining momentum, particularly in emerging markets.
  • Key players like Boehringer Ingelheim, Lonza, and WuXi Biologics are focusing on expanding capabilities and adopting advanced manufacturing technologies.
  • The market faces restraints related to high regulatory compliance costs and the complexity of manufacturing processes.
  • North America dominates the market, followed by Europe, due to established pharmaceutical industries and advanced technological infrastructure.
  • The Asia-Pacific region shows significant growth potential due to affordable manufacturing costs and a growing pharmaceutical market.

Market Drivers

Increasing Demand for Biologics

The rising demand for biologics, particularly monoclonal antibodies, gene therapies, and vaccines, is a key driver of the global biopharmaceutical contract manufacturing market. Biologics are being increasingly used in the treatment of chronic diseases, cancer, and rare disorders. For instance, the American Society of Clinical Oncology (ASCO) reports that monoclonal antibodies are becoming a standard treatment for various cancers. Their complex production processes require specialized facilities and expertise, which makes outsourcing to contract manufacturers a cost-effective and efficient solution for biopharma companies. This growing demand for biologics is expected to continue driving the market’s expansion in the coming years.

Advancements in Manufacturing Technologies

Technological advancements in biomanufacturing, including the use of continuous processing, single-use systems, and improved bioreactor technologies, are significantly enhancing the efficiency and scalability of production processes. For instance, the International Journal of Chemistry, Mathematics and Physics highlights the role of artificial intelligence in optimizing biomanufacturing processes. These innovations enable contract manufacturers to offer more cost-effective and flexible production solutions. The introduction of automated and digitally optimized production lines is improving product consistency and reducing turnaround times, which, in turn, helps meet the increasing demand for biologics in a timely manner.

Cost-Effectiveness and Outsourcing Trends

Pharmaceutical companies are increasingly outsourcing their manufacturing processes to contract manufacturers in order to reduce operational costs, minimize capital investment, and improve operational flexibility. Contract manufacturing allows companies to access state-of-the-art facilities and expertise without the need to invest in expensive infrastructure and technologies. The outsourcing trend is particularly strong among small- and medium-sized pharmaceutical companies, which lack the resources to develop their own manufacturing capabilities. This trend is expected to continue as more companies seek to optimize their operations and focus on core competencies.

Growth in Emerging Markets

The expansion of healthcare access in emerging markets is another major driver of the biopharmaceutical contract manufacturing market. As countries in Asia-Pacific, Latin America, and the Middle East continue to improve their healthcare systems, the demand for affordable and high-quality biopharmaceutical products is increasing. Contract manufacturing is becoming an attractive option for companies aiming to tap into these markets, as it allows them to scale production quickly and efficiently without the need for establishing local manufacturing facilities. Additionally, governments in emerging markets are offering incentives to attract foreign biopharma companies, further boosting the market’s growth.

Market Trends

Adoption of Personalized Medicine

One of the key trends in the global biopharmaceutical contract manufacturing market is the growing shift toward personalized medicine. As advances in genomics and biotechnology continue, the demand for customized treatments tailored to individual genetic profiles is increasing. For instance, the American Society of Clinical Oncology (ASCO) reports that personalized medicine is becoming a standard approach for various cancers. This trend is driving the need for more flexible and specialized manufacturing capabilities. Contract manufacturers are adapting by offering services that cater to small-batch production, personalized biologics, and cell and gene therapies. These manufacturers are also focusing on scalability to meet the evolving demands of personalized medicine while ensuring cost-effectiveness.

Integration of Digital Technologies

The integration of digital technologies into biopharmaceutical manufacturing processes is another emerging trend. Contract manufacturers are adopting smart manufacturing solutions, including data analytics, artificial intelligence (AI), and automation, to optimize production efficiency. For instance, the implementation of Industry 4.0 in biopharma is projected to save time and cost for designing optimal manufacturing processes. These technologies help streamline operations, enhance predictive maintenance, and improve supply chain management. Additionally, digital tools enable better monitoring of production processes, ensuring higher consistency and reducing the likelihood of errors. As digitalization continues to reshape the industry, contract manufacturers are leveraging these technologies to remain competitive and meet the increasing demand for biologics and advanced therapies.

Expansion of Cell and Gene Therapies

The rapid development of cell and gene therapies is another significant trend shaping the market. These advanced therapies, which involve modifying a patient’s genetic material to treat or prevent disease, require highly specialized manufacturing techniques. As the approval and commercialization of these therapies increase, biopharmaceutical companies are turning to contract manufacturers with the necessary expertise and infrastructure. This trend is prompting investment in facilities equipped to handle the complexities of cell and gene therapy production, ensuring that these groundbreaking treatments can reach the market at scale.

Regulatory and Quality Standards Focus

As the biopharmaceutical industry becomes more globalized, there is a growing emphasis on adhering to stringent regulatory and quality standards. Contract manufacturers are increasingly focusing on obtaining certifications and maintaining compliance with international regulations, such as Good Manufacturing Practice (GMP) and other region-specific guidelines. This trend is driven by the need for consistent product quality and patient safety, particularly in biologics and advanced therapies. Manufacturers are investing in state-of-the-art facilities and quality control processes to meet these evolving regulatory demands and ensure the safety and efficacy of products.

Market Challenges Analysis

Regulatory Compliance and Market Fragmentation

Another significant challenge in the biopharmaceutical contract manufacturing market is the complexity of regulatory compliance and market fragmentation. The biopharmaceutical industry is highly regulated, with varying standards across regions, making it difficult for contract manufacturers to navigate the complex regulatory environment. For instance, compliance with international regulations, such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) requirements, is critical for ensuring product quality and market approval. Moreover, the fragmented nature of the global biopharmaceutical market means that contract manufacturers must adapt to local regulatory standards while maintaining consistency across different regions. This complexity increases operational costs and requires continuous investments in regulatory expertise, certification processes, and quality control systems to remain competitive in an increasingly demanding market.

Supply Chain and Raw Material Constraints

One of the key challenges facing the global biopharmaceutical contract manufacturing market is the ongoing strain on supply chains, particularly in sourcing high-quality raw materials for biologics production. The production of biologics, including monoclonal antibodies and gene therapies, relies on specific and often scarce materials, such as cell culture media and other specialized reagents. Disruptions in the supply of these materials can lead to delays, increased costs, and production bottlenecks. Furthermore, global supply chain vulnerabilities, such as those highlighted by the COVID-19 pandemic, have exacerbated these issues, making it increasingly difficult for contract manufacturers to ensure timely and consistent delivery of products. This challenge is forcing contract manufacturers to diversify their supply chains and invest in more resilient sourcing strategies.

Market Opportunities

Expansion into Emerging Markets

A significant opportunity for the global biopharmaceutical contract manufacturing market lies in the expansion into emerging markets, particularly in Asia-Pacific, Latin America, and Africa. As healthcare access improves in these regions, the demand for biopharmaceutical products, including biologics and vaccines, is increasing. Contract manufacturers can capitalize on this growth by offering cost-effective, scalable production solutions tailored to the needs of local markets. Additionally, many governments in these regions are investing in healthcare infrastructure and offering incentives for foreign biopharma companies to set up manufacturing operations. By establishing a presence in these emerging markets, contract manufacturers can benefit from both local demand and regional cost advantages, positioning themselves as key players in the global supply chain.

Innovation in Advanced Therapies and Personalized Medicine

The rapid advancements in cell and gene therapies, along with the growing focus on personalized medicine, present lucrative opportunities for contract manufacturers. As these therapies gain momentum, the demand for specialized manufacturing capabilities is rising. Contract manufacturers that can offer expertise in the production of small-batch, high-complexity biologics, and customized therapies are well-positioned to capture market share in this evolving sector. Furthermore, integrating innovative technologies such as automation, artificial intelligence, and digitalization into the manufacturing process can improve efficiency and scalability, allowing contract manufacturers to meet the increasing demand for personalized and cutting-edge treatments. This focus on innovation enables contract manufacturers to differentiate themselves in a competitive market while supporting the development of groundbreaking therapies that address unmet medical needs.

Market Segmentation Analysis:

By Source:

The Global Biopharmaceuticals Contract Manufacturing market is segmented by source into two categories: mammalian and non-mammalian systems. Mammalian-based manufacturing systems are preferred for producing complex biologics like monoclonal antibodies, recombinant proteins, and vaccines due to their ability to replicate human-like post-translational modifications. This segment is expected to dominate the market because of the high demand for biopharmaceuticals that require these systems for optimal efficacy. Non-mammalian systems, such as yeast and bacteria, offer cost-effective alternatives and are particularly popular for producing less complex drugs or therapeutic proteins. These systems are growing in popularity for their shorter production cycles and lower costs, making them an attractive choice for early-phase production or biosimilar manufacturing. The market is expected to witness strong growth in both segments, driven by the increasing demand for biologics, biosimilars, and other advanced therapeutics.

By Service:

The market is also segmented based on service offerings, which include process development, downstream processing, upstream processing, fill & finish operations, analytical & QC studies, packaging & labelling, and others. Process development services are crucial in ensuring that the biopharmaceutical product is optimized for large-scale manufacturing, which is a key market driver. Downstream and upstream processing services are pivotal for the production of high-quality biologics, with downstream focusing on purification and downstream processing covering fermentation or cell culture. Fill & finish operations and packaging & labelling are essential services for ensuring product safety and compliance with regulatory standards. Analytical & QC studies ensure product quality, while other services cater to niche needs within the market. The increasing demand for customized biopharmaceuticals and high-quality manufacturing processes is expected to drive the expansion of these service segments.

Segments:

Based on Source:

  • Mammalian
  • Non-mammalian

Based on Service:

  • Process Development
  • Downstream
  • Upstream
  • Fill & Finish Operations
  • Analytical & QC studies
  • Packaging & Labelling
  • Others

Based on Drug Type:

  • Biologics
  • Monoclonal antibodies (mAbs)
  • Recombinant Proteins
  • Vaccines
  • Antisense, RNAi, & Molecular Therapy
  • Others
  • Biosimilars

Based on Type:

  • Drug Substance
  • Finished Drug Product

Based on Scale of Operation:

  • Clinical
  • Commercial

Based on Therapeutic Area:

  • Oncology
  • Autoimmune Diseases
  • Cardiovascular Diseases
  • Infectious Diseases
  • Others

Based on the Geography:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Russia
    • Belgium
    • Netherlands
    • Austria
    • Sweden
    • Poland
    • Denmark
    • Switzerland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Thailand
    • Indonesia
    • Vietnam
    • Malaysia
    • Philippines
    • Taiwan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Peru
    • Chile
    • Colombia
    • Rest of Latin America
  • Middle East
    • UAE
    • KSA
    • Israel
    • Turkey
    • Iran
    • Rest of Middle East
  • Africa
    • Egypt
    • Nigeria
    • Algeria
    • Morocco
    • Rest of Africa

Regional Analysis

North America

North America holds the largest market share in the Global Biopharmaceuticals Contract Manufacturing market, with a significant contribution from the United States. In 2023, the region accounted for approximately 45% of the total market share. This dominance can be attributed to the strong presence of leading biopharmaceutical companies, well-established infrastructure, and high investment in biopharmaceutical research and development. The U.S. is home to some of the largest contract manufacturers, including major players in mammalian and non-mammalian systems, which contributes to the region’s market leadership. Additionally, the increasing adoption of biologics and biosimilars in the region further boosts the demand for contract manufacturing services. The market in North America is expected to continue growing steadily through 2032, driven by advancements in biomanufacturing technology and increasing collaborations between pharmaceutical companies and contract manufacturers.

Europe

Europe is the second-largest region in the global biopharmaceuticals contract manufacturing market, holding a market share of approximately 30% in 2023. The growth in Europe can be attributed to the strong regulatory framework, established healthcare systems, and a growing emphasis on innovation in biologics production. The region’s manufacturing capacity is bolstered by countries like Germany, the United Kingdom, and Switzerland, which are home to top pharmaceutical companies and contract manufacturing organizations (CMOs). The growing demand for biologics, particularly monoclonal antibodies and recombinant proteins, is driving market growth. Europe is also seeing an increase in outsourcing by small and mid-sized biotech firms, which is contributing to the expansion of the contract manufacturing market. The demand for high-quality biopharmaceutical products in Europe is expected to further accelerate market growth, especially with the rise of cell and gene therapies.

Asia Pacific

The Asia Pacific region is expected to experience the highest growth rate in the biopharmaceuticals contract manufacturing market, with a market share of approximately 15% in 2023. This growth is largely driven by the increasing number of contract manufacturing organizations (CMOs) and the region’s cost-effective manufacturing solutions. Countries such as China and India are key players in this segment due to their lower production costs and well-established infrastructure for manufacturing biologics. Additionally, the growing demand for affordable healthcare solutions and biologics in the region contributes to the market’s expansion. The Asia Pacific region’s market growth is also supported by the rising investments in the pharmaceutical and biotechnology sectors, particularly in process development and manufacturing capabilities. By 2032, Asia Pacific is expected to contribute significantly to the global market, driven by increased outsourcing, favorable government policies, and advancements in biomanufacturing technologies.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa (MEA) regions together account for a smaller share of the biopharmaceuticals contract manufacturing market, contributing around 10% in 2023. However, these regions are projected to experience moderate growth over the forecast period. In Latin America, countries such as Brazil and Mexico are seeing increased investments in biopharmaceutical manufacturing, driven by expanding healthcare needs and rising demand for biologics. The Middle East and Africa also show promising growth potential, with the UAE and South Africa emerging as key markets for biopharmaceutical contract manufacturing. As healthcare infrastructures improve and demand for biopharmaceutical products increases in these regions, contract manufacturing services are expected to become more prevalent. The growth in these regions is anticipated to be driven by both regional market expansions and the outsourcing of biopharmaceutical production from North America and Europe.

Key Player Analysis

  • Boehringer Ingelheim GmbH
  • Lonza
  • Inno Biologics Sdn Bhd
  • Rentschler Biotechnologie GmbH
  • JRS PHARMA
  • AGC Biologics
  • ProBioGen
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Toyobo Co. Ltd.
  • Samsung Biologics
  • Thermo Fisher Scientific, Inc.
  • Binex Co., Ltd.
  • WuXi Biologics
  • AbbVie, Inc.
  • ADMA Biologics, Inc.
  • Catalent, Inc.
  • Cambrex Corporation
  • Pfizer Inc.
  • Siegfried Holding AG

Competitive Analysis

The competitive landscape of the global biopharmaceuticals contract manufacturing market is characterized by a mix of established players and emerging companies, each striving to expand their market share through strategic alliances, advanced technologies, and diverse service offerings. Leading players such as Boehringer Ingelheim GmbH, Lonza, WuXi Biologics, Samsung Biologics, and Thermo Fisher Scientific, Inc. dominate the market, offering end-to-end contract manufacturing services, from process development to fill & finish operations. For instance, Lonza has been recognized for its extensive experience and cutting-edge facilities, which cater to the increasing demand for biologics, vaccines, and biosimilars. These companies leverage their extensive experience, cutting-edge facilities, and broad geographic presence to cater to the increasing demand for biologics, vaccines, and biosimilars. These market leaders are focusing on enhancing operational efficiencies through technological advancements like single-use systems and continuous manufacturing techniques. Additionally, collaborations with small and mid-sized pharmaceutical companies are strengthening their position. The market is also seeing an increasing trend toward outsourcing complex manufacturing tasks such as analytical & QC studies, packaging & labeling, and downstream processing. Smaller players are striving to gain a competitive edge by offering specialized services, cost-effective solutions, and faster turnaround times. Overall, the competition is fierce, with companies aiming to maintain their dominance through innovation, service diversification, and strategic partnerships.

Recent Developments

  • In Nov 2024, FUJIFILM Diosynth Biotechnologies signed a multi-year manufacturing agreement with TG Therapeutics for BRIUMVI® production at their new Holly Springs, North Carolina facility.
  • In October 2024, Lonza extended collaboration with a major biopharmaceutical partner for ADC manufacturing.
  • In October 2024, Thermo Fisher Scientific launched comprehensive CDMO and CRO drug development solutions..
  • In July 2024, Rentschler Biopharma opened new state-of-the-art production line in Milford, Massachusetts.
  • In May 2024, AGC Biologics offering end-to-end biopharmaceutical development and manufacturing capabilities.

Market Concentration & Characteristics

The global biopharmaceuticals contract manufacturing market exhibits a moderate to high concentration, with a few dominant players controlling a significant share of the market. Major companies such as Boehringer Ingelheim GmbH, Lonza, WuXi Biologics, and Thermo Fisher Scientific, Inc. lead the market by offering comprehensive solutions across various stages of drug development and manufacturing, from process development to fill & finish operations. These key players have a global presence, large-scale production capabilities, and a proven track record in producing complex biologics and biosimilars. The market is characterized by high barriers to entry due to significant capital investment, regulatory compliance, and the need for advanced technology and skilled labor. As a result, smaller players focus on niche segments, providing specialized services such as analytical & QC studies, packaging, and labeling. Companies in this market are increasingly adopting technological advancements like continuous manufacturing and single-use systems to enhance efficiency and reduce costs. The market is also witnessing a shift towards long-term partnerships, with biopharmaceutical companies outsourcing their manufacturing to reduce operational risks and costs. This collaboration-driven model is becoming increasingly prevalent, indicating a move towards further consolidation and specialization in the market. Overall, the market remains competitive, with both large and small players striving to meet the growing demand for biopharmaceuticals.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Coverage

The research report offers an in-depth analysis based on Source, Service, Drug Type, Type, Scale of Operation, Therapeutic Area and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

  1. The global biopharmaceuticals contract manufacturing market is expected to continue growing due to increasing demand for biologics and biosimilars.
  2. Advanced manufacturing technologies, such as continuous manufacturing and single-use systems, will drive efficiencies and reduce costs.
  3. Biopharmaceutical companies will increasingly outsource production to reduce operational risks and capital expenditures.
  4. Contract manufacturers will expand their service offerings to include specialized areas like analytical & QC studies and packaging & labeling.
  5. The market will witness growing partnerships between small biotech firms and large contract manufacturers, promoting innovation and market expansion.
  6. Regulatory challenges will remain, requiring contract manufacturers to ensure compliance with international standards.
  7. Increasing investments in R&D will lead to more complex biologics and therapies, driving the need for specialized manufacturing capabilities.
  8. North America and Europe will continue to dominate the market, with a strong presence of established contract manufacturers and pharmaceutical companies.
  9. Emerging markets in Asia-Pacific and Latin America will offer growth opportunities, driven by rising healthcare demands and investment in manufacturing capabilities.
  10. Environmental sustainability will become a focus, with companies adopting green technologies and practices to reduce the ecological footprint of biopharmaceutical manufacturing.

CHAPTER NO. 1 : INTRODUCTION 34
1.1.1. Report Description 34
Purpose of the Report 34
USP & Key Offerings 34
1.1.2. Key Benefits for Stakeholders 34
1.1.3. Target Audience 35
1.1.4. Report Scope 35
1.1.5. Regional Scope 36
CHAPTER NO. 2 : EXECUTIVE SUMMARY 37
2.1. Biopharmaceuticals Contract Manufacturing Market Snapshot 37
2.1.1. Global Biopharmaceuticals Contract Manufacturing Market, 2018 – 2032 (USD Million) 38
CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 39
3.1. Russia-Ukraine and Israel-Palestine War Impacts 39
CHAPTER NO. 4 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – INDUSTRY ANALYSIS 40
4.1. Introduction 40
4.2. Market Drivers 41
4.2.1. Rising Number of Biologics 41
4.2.2. Advancements in Manufacturing Technologies 42
4.3. Market Restraints 43
4.3.1. Need for Specialized Facilities and Equipment 43
4.4. Market Opportunities 44
4.4.1. Market Opportunity Analysis 44
4.5. Porter’s Five Forces Analysis 45
CHAPTER NO. 5 : ANALYSIS COMPETITIVE LANDSCAPE 46
5.1. Company Market Share Analysis – 2023 46
5.1.1. Global Biopharmaceuticals Contract Manufacturing Market: Company Market Share, by Volume, 2023 46
5.1.2. Global Biopharmaceuticals Contract Manufacturing Market: Company Market Share, by Revenue, 2023 47
5.1.3. Global Biopharmaceuticals Contract Manufacturing Market: Top 6 Company Market Share, by Revenue, 2023 47
5.1.4. Global Biopharmaceuticals Contract Manufacturing Market: Top 3 Company Market Share, by Revenue, 2023 48
5.2. Global Biopharmaceuticals Contract Manufacturing Market Company Revenue Market Share, 2023 49
5.3. Company Assessment Metrics, 2023 50
5.3.1. Stars 50
5.3.2. Emerging Leaders 50
5.3.3. Pervasive Players 50
5.3.4. Participants 50
5.4. Start-ups /SMEs Assessment Metrics, 2023 50
5.4.1. Progressive Companies 50
5.4.2. Responsive Companies 50
5.4.3. Dynamic Companies 50
5.4.4. Starting Blocks 50
5.5. Strategic Developments 51
5.5.1. Acquisitions & Mergers 51
New Product Launch 51
Regional Expansion 51
5.6. Key Players Product Matrix 52
CHAPTER NO. 6 : PESTEL & ADJACENT MARKET ANALYSIS 53
6.1. PESTEL 53
6.1.1. Political Factors 53
6.1.2. Economic Factors 53
6.1.3. Social Factors 53
6.1.4. Technological Factors 53
6.1.5. Environmental Factors 53
6.1.6. Legal Factors 53
6.2. Adjacent Market Analysis 53
CHAPTER NO. 7 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY SOURCE SEGMENT ANALYSIS 54
7.1. Biopharmaceuticals Contract Manufacturing Market Overview, by Source Segment 54
7.1.1. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Source, 2023 & 2032 55
7.1.2. Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Source 56
7.1.3. Incremental Revenue Growth Opportunity, by Source, 2024 – 2032 56
7.1.4. Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018, 2023, 2027 & 2032 57
7.2. Mammalian 58
7.2.1. Global Mammalian Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 59
7.2.2. Global Mammalian Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 59
7.3. Non-mammalian 60
7.3.1. Global Non-mammalian Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 61
7.3.2. Global Non-mammalian Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 61
CHAPTER NO. 8 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY SERVICE SEGMENT ANALYSIS 62
8.1. Biopharmaceuticals Contract Manufacturing Market Overview, by Service Segment 62
8.1.1. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Service, 2023 & 2032 63
8.1.2. Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Service 64
8.1.3. Incremental Revenue Growth Opportunity, by Service, 2024 – 2032 64
8.1.4. Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018, 2023, 2027 & 2032 65
8.2. Process Development 66
8.2.1. Global Process Development Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 67
8.2.2. Global Process Development Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 67
8.2.3. Downstream 68
8.2.3.1. Global Downstream Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 69
8.2.3.2. Global Downstream Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 69
8.2.4. Upstream 70
8.2.4.1. Global Upstream Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 71
8.2.4.2. Global Upstream Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 71
8.3. Fill & Finish Operations 72
8.3.1. Global Fill & Finish Operations Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 73
8.3.2. Global Fill & Finish Operations Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 73
8.4. Analytical & QC studies 74
8.4.1. Global Analytical & QC studies Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 75
8.4.2. Global Analytical & QC studies Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 75
8.5. Packaging & Labelling 76
8.5.1. Global Packaging & Labelling Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 77
8.5.2. Global Packaging & Labelling Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 77
8.6. Others 78
8.6.1. Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 79
8.6.2. Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 79
CHAPTER NO. 9 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY DRUG TYPE SEGMENT ANALYSIS 80
9.1. Biopharmaceuticals Contract Manufacturing Market Overview, by Drug Type Segment 80
9.1.1. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 81
9.1.2. Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By End-user 82
9.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 82
9.1.4. Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 83
9.2. Biologics 84
9.2.1. Global Biologics Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 85
9.2.2. Global Biologics Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 85
9.2.3. Monoclonal antibodies (mAbs) 86
9.2.3.1. Global Monoclonal antibodies (mAbs) Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 87
9.2.3.2. Global Monoclonal antibodies (mAbs) Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 87
9.2.4. Recombinant Proteins 88
9.2.4.1. Global Recombinant Proteins Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 89
9.2.4.2. Global Recombinant Proteins Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 89
9.2.5. Vaccines 90
9.2.5.1. Global Vaccines Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 91
9.2.5.2. Global Vaccines Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 91
9.2.6. Antisense, RNAi, & Molecular Therapy 92
9.2.6.1. Global Antisense, RNAi, & Molecular Therapy Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 93
9.2.6.2. Global Antisense, RNAi, & Molecular Therapy Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 93
9.2.7. Others 94
9.2.7.1. Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 95
9.2.7.2. Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 95
9.3. Biosimilars 96
9.3.1. Global Biosimilars Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 97
9.3.2. Global Biosimilars Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 97
CHAPTER NO. 10 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY TYPE SEGMENT ANALYSIS 98
10.1. Biopharmaceuticals Contract Manufacturing Market Overview, by Type Segment 98
10.1.1. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Type, 2023 & 2032 99
10.1.2. Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Type 100
10.1.3. Incremental Revenue Growth Opportunity, by Type, 2024 – 2032 100
10.1.4. Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018, 2023, 2027 & 2032 101
10.2. Drug Substance 102
10.2.1. Global Drug Substance Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 103
10.2.2. Global Drug Substance Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 103
10.3. Finished Drug Product 104
10.3.1. Global Finished Drug Product Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 105
10.3.2. Global Finished Drug Product Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 105
CHAPTER NO. 11 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY SCALE OF OPERATION SEGMENT ANALYSIS 106
11.1. Biopharmaceuticals Contract Manufacturing Market Overview, by Scale of Operation Segment 106
11.1.1. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 107
11.1.2. Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Scale of Operation 108
11.1.3. Incremental Revenue Growth Opportunity, by Scale of Operation, 2024 – 2032 108
11.1.4. Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 109
11.2. Clinical 110
11.2.1. Global Clinical Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 111
11.2.2. Global Clinical Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 111
11.3. Commercial 112
11.3.1. Global Commercial Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 113
11.3.2. Global Commercial Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 113
CHAPTER NO. 12 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – BY THERAPEUTIC AREA SEGMENT ANALYSIS 114
12.1. Biopharmaceuticals Contract Manufacturing Market Overview, by Therapeutic Area Segment 114
12.1.1. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Therapeutic Area, 2023 & 2032 115
12.1.2. Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Therapeutic Area 116
12.1.3. Incremental Revenue Growth Opportunity, by Therapeutic Area, 2024 – 2032 116
12.1.4. Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018, 2023, 2027 & 2032 117
12.2. Oncology 118
12.2.1. Global Oncology Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 119
12.2.2. Global Oncology Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 119
12.3. Autoimmune Diseases 120
12.3.1. Global Autoimmune Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 121
12.3.2. Global Autoimmune Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 121
12.4. Cardiovascular Diseases 122
12.4.1. Global Cardiovascular Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 123
12.4.2. Global Cardiovascular Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 123
12.5. Infectious Diseases 124
12.5.1. Global Infectious Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 125
12.5.2. Global Infectious Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 125
12.6. Others 126
12.6.1. Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 127
12.6.2. Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 127
CHAPTER NO. 13 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – REGIONAL ANALYSIS 128
13.1. Biopharmaceuticals Contract Manufacturing Market Overview, by Regional Segments 128
13.2. Region 129
13.2.1. Global Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Region, 2023 & 2032 129
13.2.2. Biopharmaceuticals Contract Manufacturing Market Attractiveness Analysis, By Region 130
13.2.3. Incremental Revenue Growth Opportunity, by Region, 2024 – 2032 130
13.2.4. Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018, 2023, 2027 & 2032 131
13.2.5. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 132
13.2.6. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 132
13.3. Source 133
13.3.1. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 133
13.3.2. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2024 – 2032 (USD Million) 133
13.4. Service 134
13.4.1. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 134
13.4.2. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2024 – 2032 (USD Million) 134
13.5. Drug Type 135
13.5.1. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Drug Type, 2018 – 2023 (USD Million) 135
13.5.2. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Drug Type, 2024 – 2032 (USD Million) 135
13.6. Type 136
13.6.1. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 136
13.6.2. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 136
13.7. Scale of Operation 137
13.7.1. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 137
13.7.2. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 137
13.8. Therapeutic Area 138
13.8.1. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 138
13.8.2. Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 138
CHAPTER NO. 14 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – NORTH AMERICA 139
14.1. North America 139
14.1.1. Key Highlights 139
14.1.2. North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 140
14.1.3. North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 141
14.1.4. North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 142
14.1.5. North America Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 143
14.1.6. North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 144
14.1.7. North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 145
14.1.8. North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 146
14.2. U.S. 147
14.3. Canada 147
14.4. Mexico 147
CHAPTER NO. 15 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – EUROPE 148
15.1. Europe 148
15.1.1. Key Highlights 148
15.1.2. Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 149
15.1.3. Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 150
15.1.4. Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 151
15.1.5. Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 152
15.1.6. Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 153
15.1.7. Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 154
15.1.8. Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 155
15.2. UK 156
15.3. France 156
15.4. Germany 156
15.5. Italy 156
15.6. Spain 156
15.7. Russia 156
15.8. Belgium 156
15.9. Netherland 156
15.10. Austria 156
15.11. Sweden 156
15.12. Poland 156
15.13. Denmark 156
15.14. Switzerland 156
15.15. Rest of Europe 156
CHAPTER NO. 16 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – ASIA PACIFIC 157
16.1. Asia Pacific 157
16.1.1. Key Highlights 157
16.1.2. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 158
16.1.3. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 159
16.1.4. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 160
16.1.5. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 161
16.1.6. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 162
16.1.7. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 163
16.1.8. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 164
16.2. China 165
16.3. Japan 165
16.4. South Korea 165
16.5. India 165
16.6. Australia 165
16.7. Thailand 165
16.8. Indonesia 165
16.9. Vietnam 165
16.10. Malaysia 165
16.11. Philippines 165
16.12. Taiwan 165
16.13. Rest of Asia Pacific 165
CHAPTER NO. 17 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – LATIN AMERICA 166
17.1. Latin America 166
17.1.1. Key Highlights 166
17.1.2. Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 167
17.1.3. Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 168
17.1.4. Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 169
17.1.5. Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 170
17.1.6. Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 171
17.1.7. Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 172
17.1.8. Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 173
17.2. Brazil 174
17.3. Argentina 174
17.4. Peru 174
17.5. Chile 174
17.6. Colombia 174
17.7. Rest of Latin America 174
CHAPTER NO. 18 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – MIDDLE EAST 175
18.1. Middle East 175
18.1.1. Key Highlights 175
18.1.2. Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 176
18.1.3. Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 177
18.1.4. Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 178
18.1.5. Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 179
18.1.6. Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 180
18.1.7. Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 181
18.1.8. Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 182
18.2. UAE 183
18.3. KSA 183
18.4. Israel 183
18.5. Turkey 183
18.6. Iran 183
18.7. Rest of Middle East 183
CHAPTER NO. 19 : BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET – AFRICA 184
19.1. Africa 184
19.1.1. Key Highlights 184
19.1.2. Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 185
19.1.3. Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 186
19.1.4. Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 187
19.1.5. Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 188
19.1.6. Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 189
19.1.7. Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 190
19.1.8. Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 191
19.2. Egypt 192
19.3. Nigeria 192
19.4. Algeria 192
19.5. Morocco 192
19.6. Rest of Africa 192
CHAPTER NO. 20 : COMPANY PROFILES 193
20.1. Boehringer Ingelheim GmbH 193
20.1.1. Company Overview 193
20.1.2. Product Portfolio 193
20.1.3. Swot Analysis 193
20.1.4. Business Strategy 194
20.1.5. Financial Overview 194
20.2. Lonza 195
20.3. Inno Biologics Sdn Bhd 195
20.4. Rentschler Biotechnologie GmbH 195
20.5. JRS PHARMA 195
20.6. AGC Biologics 195
20.7. ProBioGen 195
20.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. 195
20.9. Toyobo Co. Ltd. 195
20.10. Samsung Biologics 195
20.11. Thermo Fisher Scientific, Inc. 195
20.12. Binex Co., Ltd. 195
20.13. WuXi Biologics 195
20.14. AbbVie, Inc. 195
20.15. ADMA Biologics, Inc. 195
20.16. Catalent, Inc 195
20.17. Cambrex Corporation 195
20.18. Pfizer Inc. 195
20.19. Siegfried Holding AG 195

List of Figures
FIG NO. 1. Global Biopharmaceuticals Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 39
FIG NO. 2. Porter’s Five Forces Analysis for Global Biopharmaceuticals Contract Manufacturing Market 46
FIG NO. 3. Company Share Analysis, 2023 47
FIG NO. 4. Company Share Analysis, 2023 48
FIG NO. 5. Company Share Analysis, 2023 48
FIG NO. 6. Company Share Analysis, 2023 49
FIG NO. 7. Biopharmaceuticals Contract Manufacturing Market – Company Revenue Market Share, 2023 50
FIG NO. 8. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Source, 2023 & 2032 56
FIG NO. 9. Market Attractiveness Analysis, By Source 57
FIG NO. 10. Incremental Revenue Growth Opportunity by Source, 2024 – 2032 57
FIG NO. 11. Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018, 2023, 2027 & 2032 58
FIG NO. 12. Global Biopharmaceuticals Contract Manufacturing Market for Mammalian, Revenue (USD Million) 2018 – 2032 59
FIG NO. 13. Global Biopharmaceuticals Contract Manufacturing Market for Non-mammalian, Revenue (USD Million) 2018 – 2032 61
FIG NO. 14. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Service, 2023 & 2032 64
FIG NO. 15. Market Attractiveness Analysis, By Service 65
FIG NO. 16. Incremental Revenue Growth Opportunity by Service, 2024 – 2032 65
FIG NO. 17. Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018, 2023, 2027 & 2032 66
FIG NO. 18. Global Biopharmaceuticals Contract Manufacturing Market for Process Development, Revenue (USD Million) 2018 – 2032 67
FIG NO. 19. Global Biopharmaceuticals Contract Manufacturing Market for Downstream, Revenue (USD Million) 2018 – 2032 69
FIG NO. 20. Global Biopharmaceuticals Contract Manufacturing Market for Upstream, Revenue (USD Million) 2018 – 2032 71
FIG NO. 21. Global Biopharmaceuticals Contract Manufacturing Market for Fill & Finish Operations, Revenue (USD Million) 2018 – 2032 73
FIG NO. 22. Global Biopharmaceuticals Contract Manufacturing Market for Analytical & QC studies, Revenue (USD Million) 2018 – 2032 75
FIG NO. 23. Global Biopharmaceuticals Contract Manufacturing Market for Packaging & Labelling, Revenue (USD Million) 2018 – 2032 77
FIG NO. 24. Global Biopharmaceuticals Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 79
FIG NO. 25. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 82
FIG NO. 26. Market Attractiveness Analysis, By End-user 83
FIG NO. 27. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 83
FIG NO. 28. Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 84
FIG NO. 29. Global Biopharmaceuticals Contract Manufacturing Market for Biologics, Revenue (USD Million) 2018 – 2032 85
FIG NO. 30. Global Biopharmaceuticals Contract Manufacturing Market for Monoclonal antibodies (mAbs), Revenue (USD Million) 2018 – 2032 87
FIG NO. 31. Global Biopharmaceuticals Contract Manufacturing Market for Recombinant Proteins, Revenue (USD Million) 2018 – 2032 89
FIG NO. 32. Global Biopharmaceuticals Contract Manufacturing Market for Vaccines, Revenue (USD Million) 2018 – 2032 91
FIG NO. 33. Global Biopharmaceuticals Contract Manufacturing Market for Antisense, RNAi, & Molecular Therapy, Revenue (USD Million) 2018 – 2032 93
FIG NO. 34. Global Biopharmaceuticals Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 95
FIG NO. 35. Global Biopharmaceuticals Contract Manufacturing Market for Biosimilars, Revenue (USD Million) 2018 – 2032 97
FIG NO. 36. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Type, 2023 & 2032 100
FIG NO. 37. Market Attractiveness Analysis, By Type 101
FIG NO. 38. Incremental Revenue Growth Opportunity by Type, 2024 – 2032 101
FIG NO. 39. Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018, 2023, 2027 & 2032 102
FIG NO. 40. Global Biopharmaceuticals Contract Manufacturing Market for Drug Substance, Revenue (USD Million) 2018 – 2032 103
FIG NO. 41. Global Biopharmaceuticals Contract Manufacturing Market for Finished Drug Product, Revenue (USD Million) 2018 – 2032 105
FIG NO. 42. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 108
FIG NO. 43. Market Attractiveness Analysis, By Scale of Operation 109
FIG NO. 44. Incremental Revenue Growth Opportunity by Scale of Operation, 2024 – 2032 109
FIG NO. 45. Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 110
FIG NO. 46. Global Biopharmaceuticals Contract Manufacturing Market for Clinical, Revenue (USD Million) 2018 – 2032 111
FIG NO. 47. Global Biopharmaceuticals Contract Manufacturing Market for Commercial, Revenue (USD Million) 2018 – 2032 113
FIG NO. 48. Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Therapeutic Area, 2023 & 2032 116
FIG NO. 49. Market Attractiveness Analysis, By Therapeutic Area 117
FIG NO. 50. Incremental Revenue Growth Opportunity by Therapeutic Area, 2024 – 2032 117
FIG NO. 51. Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018, 2023, 2027 & 2032 118
FIG NO. 52. Global Biopharmaceuticals Contract Manufacturing Market for Oncology, Revenue (USD Million) 2018 – 2032 119
FIG NO. 53. Global Biopharmaceuticals Contract Manufacturing Market for Autoimmune Diseases, Revenue (USD Million) 2018 – 2032 121
FIG NO. 54. Global Biopharmaceuticals Contract Manufacturing Market for Cardiovascular Diseases, Revenue (USD Million) 2018 – 2032 123
FIG NO. 55. Global Biopharmaceuticals Contract Manufacturing Market for Infectious Diseases, Revenue (USD Million) 2018 – 2032 125
FIG NO. 56. Global Biopharmaceuticals Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 127
FIG NO. 57. Global Biopharmaceuticals Contract Manufacturing Market Revenue Share, By Region, 2023 & 2032 130
FIG NO. 58. Market Attractiveness Analysis, By Region 131
FIG NO. 59. Incremental Revenue Growth Opportunity by Region, 2024 – 2032 131
FIG NO. 60. Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018, 2023, 2027 & 2032 132
FIG NO. 61. North America Biopharmaceuticals Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 140
FIG NO. 62. Europe Biopharmaceuticals Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 149
FIG NO. 63. Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 158
FIG NO. 64. Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 167
FIG NO. 65. Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 176
FIG NO. 66. Africa Biopharmaceuticals Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 185

List of Tables
TABLE NO. 1. : Global Biopharmaceuticals Contract Manufacturing Market: Snapshot 39
TABLE NO. 2. : Drivers for the Biopharmaceuticals Contract Manufacturing Market: Impact Analysis 43
TABLE NO. 3. : Restraints for the Biopharmaceuticals Contract Manufacturing Market: Impact Analysis 45
TABLE NO. 4. : Global Mammalian Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 61
TABLE NO. 5. : Global Mammalian Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 61
TABLE NO. 6. : Global Non-mammalian Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 63
TABLE NO. 7. : Global Non-mammalian Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 63
TABLE NO. 8. : Global Process Development Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 69
TABLE NO. 9. : Global Process Development Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 69
TABLE NO. 10. : Global Downstream Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 71
TABLE NO. 11. : Global Downstream Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 71
TABLE NO. 12. : Global Upstream Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 73
TABLE NO. 13. : Global Upstream Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 73
TABLE NO. 14. : Global Fill & Finish Operations Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 75
TABLE NO. 15. : Global Fill & Finish Operations Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 75
TABLE NO. 16. : Global Analytical & QC studies Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 77
TABLE NO. 17. : Global Analytical & QC studies Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 77
TABLE NO. 18. : Global Packaging & Labelling Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 79
TABLE NO. 19. : Global Packaging & Labelling Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 79
TABLE NO. 20. : Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 81
TABLE NO. 21. : Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 81
TABLE NO. 22. : Global Biologics Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 87
TABLE NO. 23. : Global Biologics Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 87
TABLE NO. 24. : Global Monoclonal antibodies (mAbs) Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 89
TABLE NO. 25. : Global Monoclonal antibodies (mAbs) Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 89
TABLE NO. 26. : Global Recombinant Proteins Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 91
TABLE NO. 27. : Global Recombinant Proteins Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 91
TABLE NO. 28. : Global Vaccines Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 93
TABLE NO. 29. : Global Vaccines Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 93
TABLE NO. 30. : Global Antisense, RNAi, & Molecular Therapy Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 95
TABLE NO. 31. : Global Antisense, RNAi, & Molecular Therapy Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 95
TABLE NO. 32. : Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 97
TABLE NO. 33. : Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 97
TABLE NO. 34. : Global Biosimilars Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 99
TABLE NO. 35. : Global Biosimilars Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 99
TABLE NO. 36. : Global Drug Substance Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 105
TABLE NO. 37. : Global Drug Substance Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 105
TABLE NO. 38. : Global Finished Drug Product Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 107
TABLE NO. 39. : Global Finished Drug Product Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 107
TABLE NO. 40. : Global Clinical Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 113
TABLE NO. 41. : Global Clinical Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 113
TABLE NO. 42. : Global Commercial Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 115
TABLE NO. 43. : Global Commercial Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 115
TABLE NO. 44. : Global Oncology Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 121
TABLE NO. 45. : Global Oncology Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 121
TABLE NO. 46. : Global Autoimmune Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 123
TABLE NO. 47. : Global Autoimmune Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 123
TABLE NO. 48. : Global Cardiovascular Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 125
TABLE NO. 49. : Global Cardiovascular Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 125
TABLE NO. 50. : Global Infectious Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 127
TABLE NO. 51. : Global Infectious Diseases Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 127
TABLE NO. 52. : Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 129
TABLE NO. 53. : Global Others Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 129
TABLE NO. 54. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2018 – 2023 (USD Million) 134
TABLE NO. 55. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Region, 2024 – 2032 (USD Million) 134
TABLE NO. 56. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 135
TABLE NO. 57. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2024 – 2032 (USD Million) 135
TABLE NO. 58. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 136
TABLE NO. 59. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2024 – 2032 (USD Million) 136
TABLE NO. 60. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Drug Type, 2018 – 2023 (USD Million) 137
TABLE NO. 61. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Drug Type, 2024 – 2032 (USD Million) 137
TABLE NO. 62. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 138
TABLE NO. 63. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 138
TABLE NO. 64. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 139
TABLE NO. 65. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 139
TABLE NO. 66. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 140
TABLE NO. 67. : Global Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 140
TABLE NO. 68. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 142
TABLE NO. 69. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 142
TABLE NO. 70. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 143
TABLE NO. 71. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2024 – 2032 (USD Million) 143
TABLE NO. 72. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 144
TABLE NO. 73. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2024 – 2032 (USD Million) 144
TABLE NO. 74. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 145
TABLE NO. 75. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 145
TABLE NO. 76. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 146
TABLE NO. 77. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 146
TABLE NO. 78. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 147
TABLE NO. 79. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 147
TABLE NO. 80. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 148
TABLE NO. 81. : North America Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 148
TABLE NO. 82. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 151
TABLE NO. 83. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 151
TABLE NO. 84. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 152
TABLE NO. 85. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2024 – 2032 (USD Million) 152
TABLE NO. 86. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 153
TABLE NO. 87. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2024 – 2032 (USD Million) 153
TABLE NO. 88. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 154
TABLE NO. 89. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 154
TABLE NO. 90. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 155
TABLE NO. 91. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 155
TABLE NO. 92. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 156
TABLE NO. 93. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 156
TABLE NO. 94. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 157
TABLE NO. 95. : Europe Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 157
TABLE NO. 96. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 160
TABLE NO. 97. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 160
TABLE NO. 98. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 161
TABLE NO. 99. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2024 – 2032 (USD Million) 161
TABLE NO. 100. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 162
TABLE NO. 101. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2024 – 2032 (USD Million) 162
TABLE NO. 102. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 163
TABLE NO. 103. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 163
TABLE NO. 104. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 164
TABLE NO. 105. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 164
TABLE NO. 106. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 165
TABLE NO. 107. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 165
TABLE NO. 108. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 166
TABLE NO. 109. : Asia Pacific Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 166
TABLE NO. 110. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 169
TABLE NO. 111. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 169
TABLE NO. 112. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 170
TABLE NO. 113. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2024 – 2032 (USD Million) 170
TABLE NO. 114. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 171
TABLE NO. 115. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2024 – 2032 (USD Million) 171
TABLE NO. 116. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 172
TABLE NO. 117. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 172
TABLE NO. 118. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 173
TABLE NO. 119. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 173
TABLE NO. 120. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 174
TABLE NO. 121. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 174
TABLE NO. 122. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 175
TABLE NO. 123. : Latin America Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 175
TABLE NO. 124. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 178
TABLE NO. 125. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 178
TABLE NO. 126. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 179
TABLE NO. 127. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2024 – 2032 (USD Million) 179
TABLE NO. 128. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 180
TABLE NO. 129. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2024 – 2032 (USD Million) 180
TABLE NO. 130. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 181
TABLE NO. 131. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 181
TABLE NO. 132. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 182
TABLE NO. 133. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 182
TABLE NO. 134. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 183
TABLE NO. 135. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 183
TABLE NO. 136. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 184
TABLE NO. 137. : Middle East Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 184
TABLE NO. 138. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2018 – 2023 (USD Million) 187
TABLE NO. 139. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Country, 2024 – 2032 (USD Million) 187
TABLE NO. 140. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2018 – 2023 (USD Million) 188
TABLE NO. 141. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Source, 2024 – 2032 (USD Million) 188
TABLE NO. 142. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2018 – 2023 (USD Million) 189
TABLE NO. 143. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Service, 2024 – 2032 (USD Million) 189
TABLE NO. 144. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 190
TABLE NO. 145. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 190
TABLE NO. 146. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2018 – 2023 (USD Million) 191
TABLE NO. 147. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Type, 2024 – 2032 (USD Million) 191
TABLE NO. 148. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 192
TABLE NO. 149. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 192
TABLE NO. 150. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2018 – 2023 (USD Million) 193
TABLE NO. 151. : Africa Biopharmaceuticals Contract Manufacturing Market Revenue, By Therapeutic Area, 2024 – 2032 (USD Million) 193

Frequently Asked Questions:

What is the current size of the Global Biopharmaceuticals Contract Manufacturing Market?

The global biopharmaceuticals contract manufacturing market was valued at USD 16,029.84 million in 2023 and is projected to grow to USD 58,636.37 million by 2032, reflecting a compound annual growth rate (CAGR) of 15.50%.

What factors are driving the growth of the Global Biopharmaceuticals Contract Manufacturing Market?

The market is driven by increasing demand for biologics and biosimilars, advancements in biomanufacturing technologies such as continuous processing and single-use systems, and the growing trend of outsourcing drug manufacturing to reduce costs and improve flexibility. Additional drivers include the rising prevalence of chronic diseases, the growth of personalized medicine, and expanding healthcare access in emerging markets.

What are the key segments within the Global Biopharmaceuticals Contract Manufacturing Market?

Key segments include:
• By Source: Mammalian and non-mammalian systems.
• By Service: Process development, upstream and downstream processing, fill & finish operations, analytical & QC studies, and packaging & labeling.
• By Drug Type: Biologics, monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and others.
• By Geography: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

What are some challenges faced by the Global Biopharmaceuticals Contract Manufacturing Market?

Challenges include high regulatory compliance costs, the complexity of manufacturing processes, supply chain constraints for raw materials, and the fragmented regulatory landscape across regions. Additionally, ensuring product quality and consistency while scaling production for advanced therapies like cell and gene treatments adds to operational challenges.

Who are the major players in the Global Biopharmaceuticals Contract Manufacturing Market?

Key players include Boehringer Ingelheim GmbH, Lonza, WuXi Biologics, Samsung Biologics, Thermo Fisher Scientific, Inc., Catalent, Inc., FUJIFILM Diosynth Biotechnologies, AGC Biologics, and AbbVie, Inc. These companies are leaders in offering end-to-end manufacturing solutions, including advanced technologies and global production capabilities.

Related Reports By Keyword

Middle East and Africa Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 69917

North America Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 69751

Asia Pacific Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 68833

U.S. Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 68758

Canada Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 68648

Latin America Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 68145

Japan Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 68131

UK Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 67960

Malaysia Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 67948

Related Reports

North America Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 69751

Asia Pacific Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 68833

U.S. Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 68758

Canada Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 68648

Leukemia Therapeutics Treatment Market

Published:
Report ID: 68427

Germany Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 67864

Australia Biopharmaceuticals Contract Manufacturing Market

Published:
Report ID: 67829

U.S. Occupational Health Market

Published:
Report ID: 62072

UK Occupational Health Market

Published:
Report ID: 62267

South Korea Occupational Health market

Published:
Report ID: 62069

Japan Occupational Health Market

Published:
Report ID: 62062

Germany Occupational Health Market

Published:
Report ID: 61983

Purchase Options

The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing.
$4699

To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis and multi-location access, making it an excellent choice for organizations with distributed workforce.
$5699

The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc.’s research team. It is highly recommended for organizations seeking to execute short, customized research projects related to the scope of the purchased report.
$7699

Request Free Sample

Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207

support

24/7 Research Support

sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

Get Methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN
Request Free Sample